Achieve Life Sciences/$ACHV

1D1W1MYTD1Y5YMAX

About Achieve Life Sciences

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Ticker
$ACHV
Sector
Health
Primary listing
NASDAQ
Employees
28
Headquarters
Bothell, United States
Website
www.achievelifesciences.com

ACHV Metrics

BasicAdvanced
$749M
-
-$1.81
2.23
-

What the Analysts think about ACHV

Analyst ratings (Buy, Hold, Sell) for Achieve Life Sciences stock.
Analyst projections of the future price of Achieve Life Sciences stock.

Bulls say / Bears say

The FDA’s Complete Response Letter identified no clinical efficacy or safety deficiencies, suggesting the principal regulatory obstacle is manufacturing remediation rather than a need to repeat pivotal clinical development. (Achieve Life Sciences) (ir.achievelifesciences.com)
Achieve secured up to approximately $354 million, including $180 million upfront and as much as $174 million from milestone-linked warrants, providing significant capital to support NDA resubmission, manufacturing work and commercial preparation. (SEC) (sec.gov)
The company has expanded its commercial, CMC and quality leadership, added six directors and advanced its U.S.-based manufacturing transition, improving organizational readiness for a potential 2027 launch. (Achieve Life Sciences) (ir.achievelifesciences.com)
The FDA issued a Complete Response Letter in June 2026, delaying potential approval until the first half of 2027 and leaving execution risk around resolving third-party manufacturing deficiencies and final labeling requirements. (Achieve Life Sciences) (ir.achievelifesciences.com)
The April financing strengthened liquidity but creates substantial dilution risk: Achieve issued approximately 49.4 million shares and warrants for up to approximately 49.5 million additional shares, while its June 2026 filing reported roughly 69.9 million shares subject to outstanding warrants. (SEC) (sec.gov)
Achieve remains a pre-revenue, single-product biotech with no approved commercial products; it reported an $84.9 million net loss for the first six months of 2026 and must still fund commercialization and launch execution. (Achieve Life Sciences 10-Q) (ir.achievelifesciences.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.

ACHV Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

ACHV Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

ACHV News

AllArticlesVideos

Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting

MarketBeat2 months ago

FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Planned

Benzinga3 months ago

US FDA declines to approve Achieve Life Sciences' smoking-cessation drug

Reuters3 months ago

Funds containing ACHV

Funds
Fund name
Fund size
$ACHV weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.